|
Printable version |
From: | "Osbert Sun" <osbert.sun@xtra.co.nz> |
Date: | Fri, 12 May 2000 11:17:40 +1200 |
Further to Brett's posting on Revesco, I would like
to bring to the attention of readers on this forum the latest reports from two
Brokerage firms. Both Salomon Smith Barney and BNP Equities Research rated RVS
as buy @A35c in their reports placed on the website of Revesco (http://www.revesco.com.au) on 3 May, with
SSB looking to upgrade its valuation on RVS to A68c at a later date. As pointed
out by Brett in his article, the downside risk is limited at the current market
price considering the favourable environment toward medical technology and
servicing in Australia.
Kind regards,
Osbert
|
|